SAMHD1单核苷酸多态性影响新诊断急性髓系白血病儿童的预后
研究评估了SAMHD1基因25个单核苷酸多态性(SNP)与400例新诊断急性髓系白血病(AML)儿童临床结局的关联,发现rs1291128、rs1291141和rs7265241与诱导I后微小残留病、无事件生存(EFS)或总生存(OS)显著相关;在COG-AAML1031试验854例独立队列中,rs7265241 A>G仍与EFS和OS显著相关,多变量分析显示所有SNP均为独立预测因素。
要点
- 在400例儿童AML中,SAMHD1的3个3'区SNP与诱导后MRD、EFS或OS显著相关。
- 在854例COG-AAML1031队列中,rs7265241 A>G仍与EFS和OS显著相关。
- 多变量分析中所有SNP均为临床结局的独立预测因素。
核心结论
- SAMHD1药物基因组学与儿童AML对阿糖胞苷(Ara-C)的应答相关,值得在扩大队列中进一步验证。
研究设计与样本
- 研究评估了SAMHD1基因25个SNP与来自AML02和AML08两项临床试验的400例新诊断儿童AML患者临床结局的关联。
- 在COG-AAML1031试验的854例独立队列中验证了显著SNP与EFS和OS的关联。
主要发现
- 位于SAMHD1 3'区的rs1291128、rs1291141和rs7265241在2个队列中与至少1项临床结局(诱导I后微小残留病、EFS或OS)显著相关。
- 在COG-AAML1031独立队列(n=854)中,rs7265241 A>G仍与EFS和OS显著相关。
- 多变量分析中,所有SNP均为临床结局的独立预测因素。
局限性
- 原文结论指出需要在扩大患者队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytarabine arabinoside (Ara-C) has been the cornerstone of acute myeloid leukemia (AML) chemotherapy for decades. After cellular uptake, it is phosphorylated into its active triphosphate form (Ara-CTP), which primarily exerts its cytotoxic effects by inhibiting DNA synthesis in proliferating cells. Interpatient variation in the enzymes involved in the Ara-C metabolic pathway has been shown to affect intracellular abundance of Ara-CTP and, thus, its therapeutic benefit. Recently, SAMHD1 (SAM and HD domain-containing deoxynucleoside triphosphate triphosphohydrolase 1) has emerged to play a role in Ara-CTP inactivation, development of drug resistance, and, consequently, clinical response in AML. Despite this, the impact of genetic variations in SAMHD1 on outcome in AML has not been investigated in depth. In this study, we evaluated 25 single nucleotide polymorphisms (SNPs) within the SAMHD1 gene for association with clinical outcome in 400 pediatric patients with newly diagnosed AML from 2 clinical trials, AML02 and AML08. Three SNPs, rs1291128, rs1291141, and rs7265241 located in the 3' region of SAMHD1 were significantly associated with at least 1 clinical outcome: minimal residual disease after induction I, event-free survival (EFS), or overall survival (OS) in the 2 cohorts. In an independent cohort of patients from the COG-AAML1031 trial (n = 854), rs7265241 A>G remained significantly associated with EFS and OS. In multivariable analysis, all the SNPs remained independent predictors of clinical outcome. These results highlight the relevance of the SAMHD1 pharmacogenomics in context of response to Ara-C in AML and warrants the need for further validation in expanded patient cohorts.
引用
- Marrero RJ, Cao X, Wu H, et al. SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. Blood Adv. 2023. PMID: 36689724. doi:10.1182/bloodadvances.2022009088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。